REFR:NASDAQResearch Frontiers Incorporated Analysis

Technical indicators paint a bleak picture. The 20‑day SMA (≈0.62) sits below the 50‑day SMA (≈0.73) and far beneath the 200‑day SMA (≈1.20), confirming a sustained bearish trend. RSI is around 34, hinting at oversold conditions, yet the MACD line remains under its signal line with a negative histogram, signalling continued downside momentum. The stock trades at $0.54, precariously close to the computed support level of $0.48 and well under the resistance at $0.81, while volume is rising but remains thin relative to averages.
Fundamental health is equally troubling. Revenue has collapsed by roughly 75%, margins are deeply negative, and EBITDA is a multi‑million‑dollar loss. Cash flow is negative, and although cash slightly exceeds debt, the debt‑to‑equity ratio exceeds 60%, indicating a leveraged balance sheet. The price‑to‑book ratio of over 10×, zero earnings, and a market cap under $20 M underscore severe valuation concerns, compounded by extreme 30‑day volatility (~95%) and a beta near market level.